Receptor Tyrosine Kinase (RTK) inhibitors, such as erlotinib/tarceva, have been introduced
in the past decade as a promising therapeutic option in Head and Neck Squamous Cell
Carcinoma (HNSCC), however, they lack significant efficacy as single agents. As a result,
RTK inhibitors require a combination based therapeutic approach with other treatment
modalities. To uncover such a combination of agents, we performed a high throughput
Prestwick library screen that included 1200 compounds approved by the FDA on HNSCC
cell lines and found that monensin, a coccidial antibiotic, synergistically enhanced the
cytotoxicity of erlotinib. RT-PCR revealed that monensin induced the expression of
Activation of Transcription Factor (ATF) 3 and its downstream target C/EBP homologous
protein (CHOP) which are key regulators of apoptosis. Furthermore, RNA-Seq analysis
suggests that monensin augments erlotinib cytotoxicity by disturbing lipid and sterol
biosynthesis. Therefore, identifying the mechanism of action exerted by monensin may open alternative avenues of cancer treatment.
| Identifer | oai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:OOU.#10393/24405 |
| Date | 19 August 2013 |
| Creators | Khalil, Dayekh |
| Source Sets | Library and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada |
| Language | English |
| Detected Language | English |
| Type | Thèse / Thesis |
Page generated in 0.0018 seconds